National Cancer Board
The question
To ask the Secretary of State for Health and Social Care, what key performance indicators and outcome measures will be used to assess the effectiveness of the National Cancer Board; who will be responsible for overseeing delivery of those outcomes; where information on the Board's performance will be published; and how the interests of brain cancer patients will be represented in the Board's decision-making.
Answered by Department of Health and Social Care
The National Cancer Plan, published on 4 February 2026, sets out the Government's long-term approach to improving outcomes for all cancer patients, including those affected by rare cancers such as brain tumours. As part of the plan, the Government committed to appointing a National Clinical Lead for Rare Cancers, who will be appointed in the coming months. They will support delivery of the plan’s rare cancer commitments, represent the interests of rare cancer patients, and sit on the reformed National Cancer Board.
A National Institute for Health and Care Research National Specialty Lead for Rare Cancers will be appointed by summer 2026, supporting the delivery of rare cancers research.
The National Cancer Board will oversee delivery of the National Cancer Plan, with progress reported to ministers by its independent Co-Chair and through an annual progress report published by Government. The board’s work will include patient voice and voluntary sector representation, including rare cancer charities, and the National Clinical Lead will help ensure the interests of rare cancer patients, including brain tumour patients, are reflected.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →